Publication of Supplementary Prospectus
Source: RNS
27 July 2022
Publication of Supplementary Prospectus
The following Supplementary Prospectus has been approved by the Financial Conduct Authority and is available for viewing:
Supplementary Prospectus dated 27 July 2022 (the "Supplementary Prospectus") relating to the £25,000,000,000 Euro Medium Term Note Programme of Lloyds Banking Group plc.
The Supplementary Prospectus should be read and construed in conjunction with the prospectus dated 30 June 2022 relating to the above programme (the "Base Prospectus").
To view the Supplementary Prospectus, please paste the following URL into the address bar of your browser:
http://www.rns-pdf.londonstockexchange.com/rns/9609T_1-2022-7-27.pdf
The Supplementary Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
For further information, please contact:
Investor Relations:
Douglas Radcliffe
Group Investor Relations Director
Tel: +44 (0)20 7356 1571
Email: douglas.radcliffe@lloydsbanking.com
Corporate Affairs:
Matt Smith
Head of Media Relations
Tel: +44 (0)20 7356 3522
Email: matt.smith@lloydsbanking.com
Lloyds Banking Group plc
Registered Office
The Mound
Edinburgh
EH1 1YZ
DISCLAIMER - INTENDED ADDRESSEES
Please note that the information contained in this announcement and the Supplementary Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom this announcement and the Supplementary Prospectus are not addressed. Prior to relying on the information contained in this announcement and the Supplementary Prospectus, you must ascertain from the Base Prospectus whether or not you are one of the intended addressees of the information contained in this announcement and the Supplementary Prospectus.
In particular, this announcement and the Supplementary Prospectus do not constitute an offer or invitation to subscribe for, or purchase securities in the United States or in any other jurisdiction where such an offer or invitation would be unlawful. This announcement and the Supplementary Prospectus are not for distribution in the United States. The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state of the United States of America and are subject to U.S. tax law requirements. Subject to certain exceptions, the securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons or to persons within the United States of America, as such terms are defined in Regulation S under the Securities Act. There will be no public offering of the securities in the United States.
Your right to access this service is conditional upon complying with the above requirement.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
